Search Results - "Iorga, Serban"

Refine Results
  1. 1

    The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients by Sikirica, Mirko, Iorga, Serban R, Bancroft, Tim, Potash, Jesse

    Published in BMC health services research (24-12-2014)
    “…Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure and death. In this study we estimated the health care…”
    Get full text
    Journal Article
  2. 2

    Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany by März, Winfried, Dippel, Franz-Werner, Theobald, Karlheinz, Gorcyca, Katherine, Iorga, Şerban R., Ansell, David

    Published in Atherosclerosis (01-01-2018)
    “…Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for cardiovascular (CV) events. European guidelines recommend reducing LDL-C as…”
    Get full text
    Journal Article
  3. 3

    Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan by Furst, Daniel E., Amato, Anthony A., Iorga, Şerban R., Gajria, Kavita, Fernandes, Ancilla W.

    Published in Muscle & nerve (01-05-2012)
    “…Introduction: Idiopathic inflammatory myopathies have a reported incidence of 0.1 to 1 per 100,000 person‐years and prevalence of 0.55 to 6 per 100,000 in the…”
    Get full text
    Journal Article
  4. 4

    A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease by Zaidi, Ahmar U, Glaros, Alexander K, Lee, Soyon, Wang, Taiji, Bhojwani, Rhea, Morris, Eric, Donohue, Breanne, Paulose, Jincy, Iorga, Åerban R, Nellesen, Dave

    Published in Orphanet journal of rare diseases (02-11-2021)
    “…Abstract Background and purpose Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S…”
    Get full text
    Journal Article
  5. 5

    Lifetime Costs for Treated Follicular Lymphoma Patients in the US by Eichten, Caitlin, Ma, Qiufei, Delea, Thomas E., Hagiwara, May, Ramos, Roberto, Iorga, Şerban R., Zhang, Jie, Maziarz, Richard T.

    Published in PharmacoEconomics (01-10-2021)
    “…Background and Objective The objective of this study was to estimate the lifetime costs of patients receiving treatment for follicular lymphoma (FL) in the…”
    Get full text
    Journal Article
  6. 6

    Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice by Arca, Marcello, Ansell, David, Averna, Maurizio, Fanelli, Francesca, Gorcyca, Katherine, Iorga, Şerban R., Maggioni, Aldo P., Paizis, Georges, Tomic, Radovan, Catapano, Alberico L.

    Published in Atherosclerosis (01-04-2018)
    “…Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Patients aged…”
    Get full text
    Journal Article
  7. 7

    Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice by Ferrières, Jean, Gorcyca, Katherine, Iorga, Şerban R., Ansell, David, Steen, Dylan L.

    Published in Clinical therapeutics (01-09-2018)
    “…The goal of this study was to summarize patterns of lipid-lowering therapy (LLT) usage and achievement of guideline-identified lipid goals in a 2015 general…”
    Get full text
    Journal Article
  8. 8

    Epidemiology of Systemic Sclerosis in a Large US Managed Care Population by FURST, Daniel E, FERNANDES, Ancilla W, IORGA, Serban R, GRETH, Warren, BANCROFT, Tim

    Published in Journal of rheumatology (01-04-2012)
    “…To estimate the incidence and prevalence of systemic sclerosis (SSc) in a large US managed care organization (MCO) database. Subjects with claims-based…”
    Get full text
    Journal Article
  9. 9

    Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States by Klimchak, Alexa C., Patel, Miraj Y., Iorga, Şerban R., Kulkarni, Natasha, Wong, Nathan D.

    Published in American journal of preventive cardiology (01-03-2020)
    “…National estimates of atherosclerotic cardiovascular disease (ASCVD) in the United States (US) are scarce, especially for patients grouped by cardiovascular…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population by Furst, Daniel E., Amato, Anthony A., Iorga, Şerban R., Bancroft, Tim, Fernandes, Ancilla W.

    Published in Muscle & nerve (01-10-2012)
    “…Introduction: In this study we determined the health‐care costs and resource utilization associated with idiopathic inflammatory myopathies (IIMs) in a large…”
    Get full text
    Journal Article
  13. 13

    Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population by FURST, Daniel E, FERNANDES, Ancilla W, IORGA, Serban R, GRETH, Warren, BANCROFT, Tim

    Published in Journal of rheumatology (01-12-2012)
    “…Systemic sclerosis (SSc) is a chronic autoimmune disease. The objective of our study was to estimate the medical costs and healthcare resource use of subjects…”
    Get full text
    Journal Article
  14. 14

    Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization by Bergenstal, Richard M, Fahrbach, Jessie L, Iorga, Şerban R, Fan, Ying, Foster, Shonda A

    Published in Endocrine practice (01-05-2012)
    “…To evaluate treatment patterns associated with diabetes medication regimen changes after hospitalization on the basis on preadmission hemoglobin A1c levels. In…”
    Get more information
    Journal Article
  15. 15

    Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients by Swindle, Jason P., Buzinec, Paul, Iorga, erban R., Ramaswamy, Krishnan, Panjabi, Sumeet

    Published in Current medical research and opinion (01-09-2011)
    “…Abstract Objective: To examine clinical and economic outcomes associated with angiotensin II receptor blockers (ARB). Methods: Retrospective claims data were…”
    Get full text
    Journal Article
  16. 16

    Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population by Furst, Daniel E, Clarke, Ann, Fernandes, Ancilla W, Bancroft, Tim, Gajria, Kavita, Greth, Warren, Iorga, Serban R

    Published in Journal of medical economics (01-04-2013)
    “…Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems, including the kidneys (lupus nephritis) and the…”
    Get more information
    Journal Article
  17. 17

    Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices by Patel, Pareshkumar, Raju, Aditya, Coutinho, Anna, Maegawa, Rodrigo, Lunacsek, Orsolya, Deyoung, Kathryn, Iorga, Serban, Cao, Xiting

    Published in Blood (23-11-2021)
    “…BACKGROUND: Current treatment guidelines recommend tyrosine kinase inhibitors (TKIs) as first-line and second-line treatment options for patients with chronic…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Frequency of Vaso-Occlusive Crises Is Associated with Health-Related Quality of Life in Pediatric Patients with Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers by Campbell, Andrew D., Rizio, Avery A., McCausland, Kristen L., Iorga, Serban, Yen, Glorian P., Paulose, Jincy, Lee, Soyon

    Published in Blood (23-11-2021)
    “…▪ Introduction: Pediatric patients with sickle cell disease (SCD) experience considerable disease-related burden. SCD-related morbidity is characterized by…”
    Get full text
    Journal Article
  20. 20